ViiV Healthcare to present key data that provides further support for the use of 2-drug regimens, including long-term efficacy, alongside new insights into living with HIV at IDWeek 2021

Conference Reports for NATAP


HIVR4P 2024 5th HIV Research for Prevention Conference Oct 6-10 2024 - Lima, Peru

	The role of healthcare-related experiences in willingness and preference for long-acting injectable PrEP (LA-PrEP) among transfeminine persons in the US Transgender Women's Internet Survey and Testing (TWIST) study - (10/16/24) Gap Between Oral and Injectable PrEP Awareness in US Transgender Women - Mark Mascolini (10/16/24) Managing inflammation from STIs as an HIV prevention strategy Can Cutting STI-Linked Inflammation Prevent HIV Infection? - Mark Mascolini (10/16/24) STI Risk Falls 80% After Milan MSM Get DoxyPEP Prescription - Mark Mascolini (10/16/24) Use of HIV rapid detection tests when initiating long-acting cabotegravir for HIV prevention, within an implementation science project - (10/16/24) Acceptability, adherence, preference and safety of placebo Long-Acting Pre-exposure Prophylaxis (LA-PrEP) injections and implants for HIV-prevention in South African men: the SAMURAI study - (10/16/24) HIV PEP-in-Pocket ("PIP") facilitates the de-medicalization of HIV prevention - (10/16/24) PrEP uptake and adherence among transgender women: findings from a randomized clinical trial of a multicomponent intervention (HPTN 091) PrEP Uptake Over 85% in Big US/Brazil Transgender Woman Study - Mark Mascolini (10/16/24) Greater PrEP use in a community-based needle and syringe program versus facility-based medication for opioid use disorder program for people who use drugs in Uganda - (10/16/24) PrEP choice for women in Africa: uptake of oral PrEP and PrEP ring - (10/16/24) Patterns of PrEP use among women in the context of choice: early results from CATALYST, an implementation study offering oral PrEP and PrEP ring across five African countries - (10/16/24) Provider and client perspectives on PrEP choice: quality of PrEP choice and factors influencing its provision in the CATALYST implementation study - (10/16/24) Integration of oral and injectable PrEP services for adolescents at the community level in Sao Paulo - (10/16/24) Switching between oral and injectable pre-exposure prophylaxis (PrEP) regimens in the United States: an investigation of reasons for switching in the real world - (10/12/24) Early implementation of long-acting injectable cabotegravir for HIV prevention in a safety net primary care center in U.S. South at Grady in Atlanta - (10/12/24) Pharmacokinetic superiority of a 3-month dapivirine vaginal ring (100 mg) compared to the 1-month dapivirine vaginal ring (25 mg) - (10/12/24) Short-term combination immunotherapy with broadly neutralizing antibodies and CCR5 blockade mediates ART-free viral control in infant rhesus macaques - (10/11/24) 17-Clinic US Study Pinpoints Keys to Giving Long-Acting Injected PrEP: Overcoming Challenges Integrating Injectable PrEP Into Care: Key Strategies From The PILLAR Study - Mark Mascolini (10/11/24) High CAB-LA PrEP On-Time and Retention Rates in US Urban Safety-Net Clinic Population. SF, Ward-86 - Mark Mascolini (10/11/24) Long-acting injectable Cabotegravir (CAB-LA) pilot implementation at primary healthcare level in resource-limited settings: early real-world evidence from the USAID DISCOVER-Health Project in Zambia - (10/11/24) HIV pre-exposure prophylaxis (PrEP) access preference among men who have sex with men in China: a discrete choice experiment - (10/10/24) Phase 1 dose-escalation trial to evaluate the safety, tolerability, pharmacokinetics and neutralization activity of PGDM1400LS in combination with VRC07-523LS and PGT121.414.LS in healthy participants without HIV (HVTN 140/HPTN 101) - (10/10/24) HIV Trends in Metropolitan US Cities from 2014-2022: Baseline For The Ending The Epidemic Initiative - (10/10/24) Early virologic success on ART following breakthrough infection on CAB-LA PrEP - Mark Mascolini (10/10/24) Gilead Lenacapavir Access Statement & Voluntary Licensing Agreement - (10/10/24) PURPOSE-2 & Other PURPOSE Studies - (10/10/24) Global racial, ethnic, and gender diversity among participants enrolled in the PURPOSE-2 trial of lenacapavir for pre-exposure prophylaxis (PrEP) - (10/10/24) Development of a long-acting biodegradable hydrogel injectable system for single or multi-purpose prevention of HIV and/or pregnancy - (10/10/24) Safety and tolerability of oral islatravir (ISL) once-monthly (QM) as pre-exposure prophylaxis (PrEP) in cisgender men and transgender women at elevated risk for acquiring HIV-1 - (10/10/24) Safety and tolerability of oral islatravir (ISL) once-monthly (QM) as pre-exposure prophylaxis (PrEP) in cisgender women at elevated risk for acquiring HIV-1 - (10/10/24) Twice-Yearly Lenacapavir for HIV Prevention in Cisgender Gay Men, Transgender, and Gender-Diverse People: Interim Analysis Result from the PURPOSE 2 study - (10/10/24) Scaling a non-human primate physiologically-based pharmacokinetic model of extended-release MK-2048 and combination MK-2048/vicriviroc (MK-2048A) intravaginal rings into humans using phase 1 MTN-027 and MTN-028 studies - (10/09/24) Weekly oral prophylaxis with MK-8527 protects rhesus macaques from rectal challenge with simian-human immunodeficiency virus - (10/09/24) ViiV HEALTHCARE TO TRIPLE ANNUAL SUPPLY OF LONG-ACTING HIV PREP FOR LOW- AND MIDDLE-INCOME COUNTRIES - (10/06/24) Preferences for starting daily, on-demand, and long-acting injectable HIV pre-exposure prophylaxis among transfeminine persons in the United States: results from the Transgender Women's Internet Survey and Testing (TWIST) study - (10/06/24) Preferences for telePrEP among people who access HIV self-testing in Philadelphia - (10/06/24) Implementing long-acting cabotegravir for HIV Pre-Exposure Prophylaxis in a large academic hospital-based urban HIV clinic - (10/06/24) Examples of studies - CATALYST South Africa - (10/06/24) Examples of studies - DCE results on service delivery preferences - (10/06/24) Examples of studies - Project PrEP - (10/06/24) Implementing PrEP Choice: Experiences from South Africa - (10/06/24) History of injectable contraception was associated with women's willingness to use long-acting injectable PrEP: findings from US women across nine cities - (10/06/24) Characterizing the Levels of Knowledge, Attitudes, and Behaviors Regarding the Use and Risks Associated with Oral HIV-1 Pre-Exposure Prophylaxis (PrEP) Among People Prescribed PrEP in Canada - (10/06/24) Understanding preferences for pre-exposure prophylaxis (PrEP) among people who would benefit from PrEP in the United States - (10/06/24) Interest in long-acting PrEP modalities among women in the United States with a history of injectable medication use: findings from the MACS/WIHS combined cohort study - (10/06/24) Safety, Pharmacokinetics, and Degradation of Ultra-Long-Acting Injectable, Biodegradable, and Removable In-Situ Forming Implant with Cabotegravir for HIV Prevention - (10/06/24)